Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Large Increase in Short Interest

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the recipient of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 101,700 shares, an increase of 32.4% from the October 15th total of 76,800 shares. Based on an average daily volume of 1,851,000 shares, the short-interest ratio is presently 0.1 days.

Analysts Set New Price Targets

Separately, Bank of America upgraded shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research report on Friday, September 6th. One investment analyst has rated the stock with a sell rating and seven have issued a hold rating to the company. According to data from MarketBeat.com, Bayer Aktiengesellschaft has a consensus rating of “Hold”.

Bayer Aktiengesellschaft Stock Up 0.9 %

OTCMKTS BAYRY traded up $0.05 during trading hours on Friday, hitting $5.41. The company had a trading volume of 1,870,487 shares, compared to its average volume of 1,451,287. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.27 and a quick ratio of 0.86. Bayer Aktiengesellschaft has a fifty-two week low of $5.33 and a fifty-two week high of $11.33. The business has a fifty day simple moving average of $7.34 and a 200-day simple moving average of $7.41.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.10). Bayer Aktiengesellschaft had a positive return on equity of 16.46% and a negative net margin of 2.02%. The business had revenue of $10.96 billion during the quarter. Research analysts predict that Bayer Aktiengesellschaft will post 1.33 earnings per share for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.